Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Resource Type
Article
Authors
Siena, Salvatore ; Di Bartolomeo, Maria ; Raghav, Kanwal ; Masuishi, Toshiki ; Loupakis, Fotios ; Kawakami, Hisato ; Yamaguchi, Kensei ; Nishina, Tomohiro ; Fakih, Marwan ; Elez, Elena ; Rodriguez, Javier ; Ciardiello, Fortunato ; Komatsu, Yoshito ; Esaki, Taito ; Chung, Ki ; Wainberg, Zev ; Sartore-Bianchi, Andrea ; Saxena, Kapil ; Yamamoto, Eriko ; Bako, Emarjola ; Okuda, Yasuyuki ; Shahidi, Javad ; Grothey, Axel ; Yoshino, Takayuki
Source
In The Lancet Oncology June 2021 22(6):779-789
Subject
Primary Research Articles
Language
ISSN
1470-2045